Form 4: Director Wayne Burris Receives Orthofix Stock Award

Orthofix Medical Inc. director Wayne Burris was granted 14,965 deferred stock units as part of a standard equity compensation award.

Summary

• Director Wayne Burris acquired 14,965 deferred stock units on June 10, 2026.
• The award represents a contingent right to receive one share of common stock per unit.
• The units vest in full on the first anniversary of the grant date, contingent upon continued service.
• Following this transaction, the director's total beneficial ownership increased to 65,504 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine equity grant for a board member.

Risks

• Vesting is subject to the reporting person's continued service through the first anniversary of the grant date.

Future Outlook

The deferred stock units will vest on June 10, 2027, and will settle into common stock within 45 days of the director's eventual termination of service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the medical device industry to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant of deferred stock units is consistent with standard compensation packages for independent directors at mid-cap medical technology firms.
• The vesting schedule of one year is typical for director equity awards in the healthcare sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 14,965 deferred stock units on June 10, 2027.

Key Dates

Keywords

Orthofix Medical, OFIX, Form 4, Insider Trading, Director Compensation, Equity Award